de Citigroup Charles River Laboratories CRL Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 71.7 M | Comprar |
316,217
+234,906
| +289% | +USD 41.8 M | 0.02% | 593 |
|
|
2026
Q1 | USD 14 M | Comprar |
81,311
+32,372
| +66% | +USD 6 M | 0.01% | 1268 |
|
|
2025
Q4 | USD 9.8 M | Comprar |
48,939
+13,101
| +37% | +USD 2.38 M | ﹤0.01% | 1554 |
|
|
2025
Q3 | USD 5.61 M | Vender |
35,838
-110,759
| -76% | -USD 17.6 M | ﹤0.01% | 1892 |
|
|
2025
Q2 | USD 22.2 M | Vender |
146,597
-87,913
| -37% | -USD 11.7 M | 0.01% | 913 |
|
|
2025
Q1 | USD 35.3 M | Vender |
234,510
-10,150
| -4% | -USD 1.7 M | 0.02% | 705 |
|
|
2024
Q4 | USD 45.2 M | Comprar |
244,660
+8,519
| +4% | +USD 1.64 M | 0.03% | 560 |
|
|
2024
Q3 | USD 46.5 M | Comprar |
236,141
+22,788
| +11% | +USD 4.74 M | 0.03% | 557 |
|
|
2024
Q2 | USD 44.1 M | Comprar |
213,353
+10,736
| +5% | +USD 2.43 M | 0.03% | 541 |
|
|
2024
Q1 | USD 54.9 M | Comprar |
202,617
+20,918
| +12% | +USD 5 M | 0.04% | 443 |
|
|
2023
Q4 | USD 43 M | Comprar |
181,699
+95,203
| +110% | +USD 18.7 M | 0.03% | 520 |
|
|
2023
Q3 | USD 17 M | Comprar |
86,496
+65,922
| +320% | +USD 13.5 M | 0.01% | 856 |
|
|
2023
Q2 | USD 4.33 M | Vender |
20,574
-9,146
| -31% | -USD 1.82 M | ﹤0.01% | 1589 |
|
|
2023
Q1 | USD 6 M | Comprar |
29,720
+10,830
| +57% | +USD 2.45 M | ﹤0.01% | 1402 |
|
|
2022
Q4 | USD 4.12 M | Vender |
18,890
-12,533
| -40% | -USD 2.74 M | ﹤0.01% | 1564 |
|
|
2022
Q3 | USD 6.18 M | Comprar |
31,423
+13,001
| +71% | +USD 2.81 M | ﹤0.01% | 1426 |
|
|
2022
Q2 | USD 3.94 M | Vender |
18,422
-4,143
| -18% | -USD 1.01 M | ﹤0.01% | 1671 |
|
|
2022
Q1 | USD 6.41 M | Vender |
22,565
-1,907
| -8% | -USD 588 k | ﹤0.01% | 1533 |
|
|
2021
Q4 | USD 9.22 M | Vender |
24,472
-27,480
| -53% | -USD 10.7 M | ﹤0.01% | 1431 |
|
|
2021
Q3 | USD 21.4 M | Comprar |
51,952
+4,132
| +9% | +USD 1.72 M | 0.01% | 951 |
|
|
2021
Q2 | USD 17.7 M | Comprar |
47,820
+25,389
| +113% | +USD 8.48 M | 0.01% | 1066 |
|
|
2021
Q1 | USD 6.5 M | Comprar |
22,431
+11,258
| +101% | +USD 3.13 M | ﹤0.01% | 1628 |
|
|
2020
Q4 | USD 2.79 M | Vender |
11,173
-657
| -6% | -USD 156 k | ﹤0.01% | 2544 |
|
|
2020
Q3 | USD 2.68 M | Vender |
11,830
-8,987
| -43% | -USD 1.87 M | ﹤0.01% | 2389 |
|
|
2020
Q2 | USD 3.63 M | Vender |
20,817
-1,371
| -6% | -USD 219 k | ﹤0.01% | 2166 |
|
|
2020
Q1 | USD 2.8 M | Comprar |
22,188
+6,624
| +43% | +USD 993 k | ﹤0.01% | 2170 |
|
|
2019
Q4 | USD 2.38 M | Vender |
15,564
-1,981
| -11% | -USD 274 k | ﹤0.01% | 2794 |
|
|
2019
Q3 | USD 2.32 M | Vender |
17,545
-28,059
| -62% | -USD 3.76 M | ﹤0.01% | 2692 |
|
|
2019
Q2 | USD 6.47 M | Comprar |
45,604
+28,090
| +160% | +USD 3.81 M | 0.01% | 1760 |
|
|
2019
Q1 | USD 2.54 M | Vender |
17,514
-7,164
| -29% | -USD 941 k | ﹤0.01% | 2424 |
|
|
2018
Q4 | USD 2.79 M | Vender |
24,678
-7,225
| -23% | -USD 905 k | ﹤0.01% | 2352 |
|
|
2018
Q3 | USD 4.29 M | Vender |
31,903
-308
| -1% | -USD 38 k | ﹤0.01% | 2004 |
|
|
2018
Q2 | USD 3.62 M | Comprar |
32,211
+971
| +3% | +USD 105 k | ﹤0.01% | 2140 |
|
|
2018
Q1 | USD 3.34 M | Vender |
31,240
-7,039
| -18% | -USD 759 k | ﹤0.01% | 2141 |
|
|
2017
Q4 | USD 4.19 M | Comprar |
38,279
+23,520
| +159% | +USD 2.56 M | ﹤0.01% | 2000 |
|
|
2017
Q3 | USD 1.59 M | Comprar |
14,759
+899
| +6% | +USD 92.4 k | ﹤0.01% | 2901 |
|
|
2017
Q2 | USD 1.4 M | Vender |
13,860
-4,033
| -23% | -USD 371 k | ﹤0.01% | 2958 |
|
|
2017
Q1 | USD 1.61 M | Vender |
17,893
-6,278
| -26% | -USD 533 k | ﹤0.01% | 2690 |
|
|
2016
Q4 | USD 1.84 M | Vender |
24,171
-1,944
| -7% | -USD 148 k | ﹤0.01% | 3050 |
|
|
2016
Q3 | USD 2.18 M | Comprar |
26,115
+12,242
| +88% | +USD 1.03 M | ﹤0.01% | 2435 |
|
|
2016
Q2 | USD 1.14 M | Comprar |
13,873
+4,970
| +56% | +USD 409 k | ﹤0.01% | 2823 |
|
|
2016
Q1 | USD 676 k | Vender |
8,903
-11,196
| -56% | -USD 829 k | ﹤0.01% | 3794 |
|
|
2015
Q4 | USD 1.62 M | Comprar |
20,099
+19,634
| +4,222% | +USD 1.42 M | ﹤0.01% | 2651 |
|
|
2015
Q3 | USD 30 k | Vender |
465
-4,083
| -90% | -USD 293 k | ﹤0.01% | 5741 |
|
|
2015
Q2 | USD 320 k | Vender |
4,548
-6,971
| -61% | -USD 516 k | ﹤0.01% | 4085 |
|
|
2015
Q1 | USD 913 k | Comprar |
11,519
+434
| +4% | +USD 32 k | ﹤0.01% | 3168 |
|
|
2014
Q4 | USD 706 k | Vender |
11,085
-13,806
| -55% | -USD 865 k | ﹤0.01% | 3520 |
|
|
2014
Q3 | USD 1.49 M | Comprar |
24,891
+15,795
| +174% | +USD 904 k | ﹤0.01% | 2761 |
|
|
2014
Q2 | USD 487 k | Vender |
9,096
-9,922
| -52% | -USD 544 k | ﹤0.01% | 3480 |
|
|
2014
Q1 | USD 1.15 M | Vender |
19,018
-3,254
| -15% | -USD 190 k | ﹤0.01% | 2769 |
|
|
2013
Q4 | USD 1.18 M | Comprar |
22,272
+18,101
| +434% | +USD 909 k | ﹤0.01% | 3026 |
|
|
2013
Q3 | USD 193 k | Vender |
4,171
-1,993
| -32% | -USD 91.5 k | ﹤0.01% | 4181 |
|
|
2013
Q2 | USD 253 k | Comprar |
+6,164
| Nuevas | +USD 264 k | ﹤0.01% | 4075 |
|
Otros fondos que tienen CRL en su cartera
Posición de Citigroup en CRL: resumen de T2 2026
Citigroup aumentó su participación en Charles River Laboratories (CRL) en 289% durante T2 2026, al comprar aproximadamente USD 41.8 M y elevar la posición a 316,217 acciones con un valor de USD 71.7 M. La posición representa 0.02% de la cartera y ocupa el puesto #593.
Citigroup reportó por primera vez una posición en CRL en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 571 fondos que sigue Wall St. Rank mantienen una posición en CRL.
- Al cierre de T2 2026, Citigroup tenía 316,217 acciones de Charles River Laboratories con un valor de USD 71.7 M.
- Citigroup compró 234,906 acciones de Charles River Laboratories en T2 2026, por un monto estimado de USD 41.8 M.
- Charles River Laboratories representó 0.02% de la cartera de Citigroup en T2 2026 y fue su posición número 593.
- Citigroup reportó por primera vez una posición en Charles River Laboratories en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 571 fondos que sigue Wall St. Rank tenían Charles River Laboratories en cartera.
Según el Informe 13F de Citigroup correspondiente a T2 2026, presentado el 3 ago 2026.